Ambys Medicines Completes $47 Million Series A Extension
SOUTH SAN FRANCISCO — Ambys Medicines, a company pioneering cell-based therapies for severe liver diseases, has completed a $47 million extension of its Series A financing. This brings the total...
Read moreDetails









